Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Pediatrics/Neonatology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Leukemia (Pediatric) Clinical Trials

A listing of Leukemia (Pediatric) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (46) clinical trials

Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy

This is a pilot study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) in patients with relapsed or refractory CD19+ leukemia and lymphoma that was previously treated with cell therapy. This study is targeting pediatric patients aged 1-24 years with CD19+ B cell malignancies with no available ...

Phase

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR Advanced B-Cell NHL ALL and CLL (SAGAN)

Patients will give the investigators blood to make CD19 CD28 (with and without CD137) chimeric receptor-T cells in the laboratory. These cells will be grown and frozen. To make the T cells, investigators will take blood (or blood from a donor) and stimulate it with growth factors to make the ...

Phase

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Despite progress has been made to date in the treatment of patients with B cell malignancies, including leukemia and lymphoma, many patients with relapsed or refractory diseases do not respond to the standard treatments. It has been shown that anti-CD19 CAR-transduced T cells may be an effective approach to treat ...

Phase

Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia

Third generation CAR-T has stronger effect of anti-tumor capacity. While people have been able to control the clinical complications now, so conducting third generation CAR-T clinical trials has a strong demand and value. The investigators construct a third generation CAR containing both CD28 and CD137.

Phase

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib Dasatinib and Prednisone

This is a Phase I, single-center, open label, prospective, single-arm, dose-escalation and multi-dose study evaluating the use of ibrutinib in combination with dasatinib and prednisone therapy.

Phase

Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia

This is a single arm, open-label, multi-center, phase I study to determine the efficacy of CTL019 in patients with r/r B-cell ALL. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Primary Follow-up, Secondary Follow-up (if applicable) and Survival Follow-up.

Phase

Pilot Study for Patients With Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma

This is an open label, single center, pilot study to evaluate the safety and tolerability, and differential persistence and engraftment of autologous T cells engineered to express a chimeric antigen receptor targeting CD19 which is linked either to the CD3 or CD3:4-1BB signaling chains in a competitive repopulation setting in ...

Phase

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

This research study tests an investigational drug called DS-3201b. An investigational drug is a medication that is still being studied and has not yet been approved by the United States Food and Drug Administration (FDA). The FDA allows DS-3201b to be used only in research. It is not known if ...

Phase

Palbociclib and Sorafenib Decitabine or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of various combinations with palbociclib in patients with relapsed and refractory leukemias. SECONDARY OBJECTIVES: I. To assess pharmacodynamic effects of palbociclib on the Cyclin-CDK-Rb axis in leukemic blasts of patients with relapsed/refractory (R/R) leukemias. II. ...

Phase

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

The purpose of this study is to evaluate the safety and tolerability of ascending doses of UCART19 (dose-escalation part) given as a single infusion in patients with relapsed / refractory (R/R) B-cell acute lymphoblastic leukaemia (B-ALL), to determine the maximum tolerated dose (MTD), the recommended dose and the lymphodepletion regimen.

Phase